We are recruiting participants with Crohn’s disease for a clinical trial to test a potential new treatment.

Site Specific Immunomodulators (SSIs) aim to reboot the body’s own immune response.

272 patients have been treated with SSI therapy in a compassionate use program.

  • Very good safety profile to date
  • 10 people with Crohn's disease were treated through a compassionate use program
  • 7 of the 10 had clinical remission
  • 4 have had sustained clinical remission after discontinuing all treatments
  • The longest case of remission is ongoing after nearly 3 years

Crohn’s Disease Research Trial

Our clinical trial involves Site Specific Immunomodulators (SSIs), a novel class of immunotherapy treatment. SSIs are being developed to stimulate the immune system in a targeted manner to reverse the chronic inflammation underlying many conditions, such as Crohn’s disease.

Sixty participants are being recruited into a Phase 1/2 clinical trial for the treatment of Crohn's disease. The trial is open to Canadian and U.S. residents living with Crohn's disease. Learn more about who can participate in this clinical trial.

If you live outside Canada or the United States and are interested in participating in this clinical trial, you can complete the assessment questionnaire and register so we may place you on our waitlist for international participants.

Listen to an interview with Dr. Hal Gunn